Seclidemstat is an investigational drug.
There have been 5 clinical trials for Seclidemstat.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 15th 2022.
The most common disease conditions in clinical trials are Liposarcoma, Histiocytoma, Benign Fibrous, and Sarcoma, Ewing. The leading clinical trial sponsors are Salarius Pharmaceuticals, LLC, HonorHealth Research Institute, and M.D. Anderson Cancer Center.